<DOC>
	<DOCNO>NCT01035411</DOCNO>
	<brief_summary>This clinical study aid future formulation development optimisation AZD9668 tablet evaluate possible effect minor change formulation process rate extent absorption .</brief_summary>
	<brief_title>AZD9668 Relative Bioavailability</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Provision inform consent prior studyspecific procedure female subject may nonchild bear potential ( i.e . post menopausal surgically sterile ) child bear potential Body mass index ( BMI ) ≥18.0 ≤30.0 kg/m2 calculate height weight screen visit ; minimum weight 50 kg . Clinically normal physical laboratory finding judge investigator , include negative test result drugofabuse , alcohol , cotinine negative test result Hepatitis B surface antigen , antibody Hepatitis C virus antibody HIV1/2 screen visit Be none smoker exsmoker stop smoke &gt; 6 month prior visit 2 ( preentry ) Any clinically significant disease disorder ( eg infections/viral disease , cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , malignant , psychiatric , major physical impairment ) , opinion investigator , may either put subject risk participation study , influence absorption , distribution , metabolism excretion drug . Any clinically relevant abnormal finding physical examination , vital sign , clinical chemistry , haematology , urinalysis , , opinion investigator , may put subject risk his/her participation study Any ECG abnormality ( include cardiac arrhythmia ) opinion investigator may put subject risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>COPD</keyword>
</DOC>